Research Article
Real-World Assessment of Clinical Outcomes in Patients with Lower-Risk Myelofibrosis Receiving Treatment with Ruxolitinib
Table 3
Specific adverse events during ruxolitinib treatment.
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
IPSS, International Prognostic Scoring System. Defined as a platelet count < 50 × 109/L at any point after ruxolitinib initiation through last ruxolitinib dose. Defined as hemoglobin < 8 g/dL at any point after ruxolitinib initiation through last ruxolitinib dose. |